>>Royalty Pharma at one point was looking to go public but don't know if they decided wasn't worth the trouble and they probably don't need the cash now.
At one point there was some weird securities law technicality that made it hard for this type of company to go public - don't know if that is still the case.
Incidentally, Tom Neff (FGEN CEO) founded the predecessors of what eventually became Royalty Pharma.
Also sold LGND to early... I think the star is their business model. Having flat expenses and growing revenues driven by higher royalties leads to a acceleration of profits + royalties are tiered and now growing in higher percentage ranges (Promacta, Kyprolis) which again accelerates growths of profits. Not so sure about the significance of their royalties for the BACE program (they got it from the Pharmacopeia merger). Would be surprised if it is bigger then 2%. But meaningful anyway. One other royalty generating stock i like is Skyepharma.
Morphosys and ARRY als have big partnered pipelines...
Market Data 
Markets 
AI
